Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.

Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N.

J Gastroenterol. 2014 Jun;49(6):1074-80. doi: 10.1007/s00535-013-0857-3. Epub 2013 Jul 12.

PMID:
23846547
2.

Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.

Nakamura A, Shibuya K, Matsuo Y, Nakamura M, Shiinoki T, Mizowaki T, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):369-75. doi: 10.1016/j.ijrobp.2011.12.026. Epub 2012 Feb 28.

PMID:
22381898
3.

Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.

Nichols RC Jr, George TJ, Zaiden RA Jr, Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS.

Acta Oncol. 2013 Apr;52(3):498-505. doi: 10.3109/0284186X.2012.762997.

PMID:
23477361
4.

Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.

Huang J, Robertson JM, Ye H, Margolis J, Nadeau L, Yan D.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1120-5. doi: 10.1016/j.ijrobp.2011.09.022. Epub 2011 Nov 16.

PMID:
22099048
5.

Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.

Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):801-8. Epub 2007 Mar 26.

PMID:
17379445
6.

A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.

Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, Niwa Y, Takatori K, Kitajima N, Sirakawa S, Yonson K, Hishikawa Y, Abe M, Sasaki R, Sugimura K, Murakami M.

Radiother Oncol. 2012 Apr;103(1):25-31. doi: 10.1016/j.radonc.2011.12.029. Epub 2012 Jan 31.

PMID:
22300608
7.

Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.

Gurka MK, Collins SP, Slack R, Tse G, Charabaty A, Ley L, Berzcel L, Lei S, Suy S, Haddad N, Jha R, Johnson CD, Jackson P, Marshall JL, Pishvaian MJ.

Radiat Oncol. 2013 Mar 1;8:44. doi: 10.1186/1748-717X-8-44.

8.

[A case of interstitial lung disease associated with gemcitabine treatment in a patient with locally advanced pancreatic cancer following proton beam radiotherapy].

Tanaka M, Matsumoto I, Shinzeki M, Toyama H, Asari S, Goto T, Shirakawa S, Yamashita H, Sawa H, Ueno K, Takahashi M, Tsuchida S, Kido M, Ajiki T, Fukumoto T, Ku Y.

Gan To Kagaku Ryoho. 2012 Nov;39(12):2158-60. Japanese.

PMID:
23268009
9.

Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.

Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1343-51. doi: 10.1016/j.ijrobp.2010.07.1986. Epub 2010 Oct 8.

PMID:
20934268
10.

[Concurrent chemoradiotherapy using full-dose gemcitabine for patients with unresectable pancreatic cancer].

Yamazaki H, Nishiyama K, Koizumi M.

Nihon Igaku Hoshasen Gakkai Zasshi. 2004 May;64(4):216-9. Japanese.

PMID:
15211883
11.

A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.

Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R.

Am J Clin Oncol. 2005 Jun;28(3):234-41.

PMID:
15923794
12.

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16. Epub 2007 Mar 23.

PMID:
17363191
13.

Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.

Beane JD, Griffin KF, Levy EB, Pandalai P, Wood B, Abi-Jaoudeh N, Beresnev T, Shutack Y, Webb CC, Avital I, Rudloff U.

Invest New Drugs. 2015 Feb;33(1):109-18. doi: 10.1007/s10637-014-0157-7. Epub 2014 Sep 19.

14.

A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.

Nagakawa Y, Hosokawa Y, Nakayama H, Sahara Y, Takishita C, Nakajima T, Hijikata Y, Kasuya K, Katsumata K, Tokuuye K, Tsuchida A.

Cancer Chemother Pharmacol. 2017 May;79(5):951-957. doi: 10.1007/s00280-017-3288-7. Epub 2017 Apr 4.

PMID:
28378027
15.

Gemcitabine-related radiation recall in a patient with pancreatic cancer.

Saif MW, Sellers S, Russo S.

Anticancer Drugs. 2006 Jan;17(1):107-11.

PMID:
16317298
16.

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly M, Lee JE, Wolff RA.

J Clin Oncol. 2006 Mar 1;24(7):1145-51.

PMID:
16505434
17.
18.

Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.

Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22.

PMID:
11483344
19.

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.

Ann Surg. 2009 Jul;250(1):88-95. doi: 10.1097/SLA.0b013e3181ad65cc.

PMID:
19561477
20.

A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.

Roxburgh P, Lumsden GR, Paul J, Harden S, Sweeting L, James A, Crellin A, Morrison R, Evans TR, McDonald AC.

Cancer Chemother Pharmacol. 2014 Jul;74(1):131-9. doi: 10.1007/s00280-014-2470-4. Epub 2014 May 13.

PMID:
24819683

Supplemental Content

Support Center